01-10-2026 18:39 via medpagetoday.com

Efgartigimod Shows Sustained Efficacy in Myasthenia Gravis Subtypes

(MedPage Today) -- Intravenous efgartigimod (Vyvgart) continued to demonstrate efficacy and safety in patients with generalized myasthenia gravis who did not have detectable anti-acetylcholine receptor (AChR) antibodies, data from the open-label...
Read more »

Medical news



Greek Life's Darkest Secret Isn’t Just Violence. It's Biohazards.
FDA Approves Only Surgical Pulmonary Valve Fit for Growing Kids
Striking Weight Loss Seen With Combo Drug in Diabetes Trial
GLP-1s Tied to Detached Fingernails in New Study
Docs Condemn 'Cornell 7'; Patient Zero vs Primary Case; Top 10 Natural Laxatives
Doctors Push Back on RFK Jr.'s AI Comments
Assessing Pathology and How It Impacts Early HER2 Breast Cancer Treatment
Novel GIP/GLP-1 Yields Uneven Findings in Diabetes Patients With Obesity
New Gastro Guidelines; Best First-Line Option in UC? Late-Stage Trial Win for Hep D
More New Moms Are Starting GLP-1 Drugs
Cemdisiran Linked With Fewer Hospitalizations in Myasthenia Gravis Study
Drug Approval for Painful Heart Condition Expands to Kids
What Is a 'Tick Bomb' and Does It Cause Disease?
Nurse Choked With Stethoscope; $15M Award for Blinded Patient; Fake Ozempic Charges
Desktop versie